UCB
UCB is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at UCB.
UCB is a company.
Key people at UCB.
UCB is a global biopharmaceutical company headquartered in Brussels, Belgium, focused on discovering and developing innovative medicines for severe diseases in immunology and neurology.[1][4][5] With over 9,000 employees across approximately 40 countries, it generated €6.1 billion in revenue in 2024 and is listed on Euronext Brussels (symbol: UCB).[1][2] UCB's mission is to create value for patients living with these conditions, enabling them to live as freely as possible from disease challenges, through R&D in neurology and immunology, recent FDA approvals (15 since 2017, including eight in the past two years), and major investments like a $5 billion U.S. expansion for biologics manufacturing that will create 300 permanent high-skilled jobs.[1][2][3]
The company serves patients with immune system and central nervous system disorders via key products such as BIMZELX®, FINTEPLA®, RYSTIGGO®, ZILBRYSQ®, EVENITY®, BRIVIACT®, and CIMZIA®, with 2025 guidance projecting at least €7 billion in revenue driven by these growth drivers.[3][5] UCB also operates UCB Ventures, investing in early-stage startups in the US and Europe to advance transformative technologies for severe diseases.[5][6]
UCB originated in Belgium and has evolved into a biopharmaceutical leader, with its U.S. presence accelerating since 2017 through a 73% workforce expansion to around 2,000 employees, supported by $4.5 billion in acquisitions and capital investments.[1][2] This growth has bolstered innovation, yielding 15 FDA approvals or expansions for severe disease treatments.[1][2] Under CEO Jean-Christophe Tellier, UCB emphasizes patient-centric purpose: "creating value for patients now and into the future."[1][2] Key milestones include scaling U.S. manufacturing partnerships and recent upgrades to 2025 financial guidance based on strong performance from pipeline assets.[3][5]
UCB rides the wave of biologics and precision medicine trends in immunology and neurology, where demand for treatments addressing autoimmune disorders (e.g., hidradenitis suppurativa) and neurological conditions (e.g., prolonged seizures, CDKL5 deficiency) surges amid aging populations and advancing science.[1][5] Timing aligns with U.S. biomedical innovation incentives, as seen in its manufacturing push amid supply chain vulnerabilities post-pandemic and IRA/340B policy impacts.[1][2][3] Market forces like gross margin improvements and R&D investment favor UCB's model, influencing the ecosystem through job creation, FDA successes, and venture funding that accelerates startup therapies into clinical pipelines.[1][5][6]
UCB's trajectory points to sustained growth via pipeline launches, U.S. biologics scaling, and BIMZELX® expansions, with trends like AI-driven drug discovery and sustainability shaping its path.[3][5] Influence may evolve through deeper venture ecosystem integration and global supply chain leadership, potentially elevating its role in transforming severe disease care. This builds on its core purpose of patient value creation, positioning UCB as a biopharma powerhouse.[1][4]
Key people at UCB.
